Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

  1. Rare Cancers Europe is not a registered organisation or legal entity but an informal European multi-stakeholder partnership initiative composed of independent national and international organisations, societies, groups, networks, institutions and companies.
  2. Rare Cancers Europe is an initiative that brings together European stakeholders with a common aim and commitment to raise awareness about the burden of rare cancers and to tackle rare cancers as an EU health priority. To ensure equal and fair representation, all stakeholders whose objectives align with the overarching goals of Rare Cancers Europe are welcome to join the initiative. However, in order to obtain balanced stakeholder representation, partners representing a specific organisation or interest area shall as far as possible be represented by umbrella organisations operating across multiple European countries. Where European organisations do not exist, national rare cancer groups are welcome as partners.
  3. The initiative is based on the understanding that its main mode of operation is “working together in partnership”.
  4. All decisions directly or indirectly affecting the partnership (strategy, projects, activities, etc.) are based on the majority of votes and always taken in a fully transparent fashion. This also applies to decisions taken by any working group, task force, committee or other body created by the partnership.
  5. The European Society for Medical Oncology (ESMO) leads the initiative, runs its Secretariat and serves as the partnership’s fiscal agent. The ESMO Management Team is responsible for day to day activities, administrative decisions, fundraising and budget preparation.
  6. The partners are all represented and work together as equal partners. Moreover, a Steering Committee provides guidance, and oversees the overall scope of the initiative.
  7. Partnership decisions require a majority of two-thirds of the members of the Partnership Council. Each partner has one vote
  8. Decisions can be taken either face-to-face at the annual partnership meetings, or by email. Meeting agendas are drafted by the Secretariat and circulated to all partners two weeks prior to the meeting for review, comments and approval.
  9. Progress reports are prepared by the Secretariat and circulated to all partners at least on a bi-annual basis.
  10. It is not foreseen that individual partners, groups of partners, or bodies created by the partnership take decisions on behalf of the partnership, unless all partners were given the opportunity to express their views concerning the decisions in question.
  11. Grant agreements with corporate supporters are based on the understanding that the grant activity will be “independent, non-promotional and free from commercial influence or bias”. There are no governance-related privileges foreseen for corporate supporters.
  12. There are no governance-related privileges foreseen for founding partners.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings